Last updated: February 22, 2026
What is NDC 16714-0526?
NDC 16714-0526 is a biological product marketed as Blenrep (belantamab mafodotin), a monoclonal antibody-drug conjugate developed by GlaxoSmithKline (GSK). It is indicated for heavily pretreated multiple myeloma patients who have received at least four prior therapies.
Current Market Position
Regulatory Status
- Approved by the U.S. Food and Drug Administration (FDA) in August 2020.
- Approved under accelerated pathway for relapsed or refractory multiple myeloma.
- Revenue from initial launches projected to be significant within the hematology-oncology segment.
Competitive Landscape
- Competes with CAR T-cell therapies such as Abecma (idecabtagene vicleucel) and traditional treatments like proteasome inhibitors.
- No direct biosimilar counterparts as of 2023 due to the novelty and patent protections.
Market Size
- Multiple myeloma treatment market valued at approximately $9 billion globally in 2022.
- In the U.S., the multiple myeloma segment accounts for nearly $4 billion.
- Belantamab mafodotin targets a niche with high unmet needs within this market.
Key Drivers
- Increasing prevalence of multiple myeloma, with an estimated 35,000 new cases annually in the U.S.[1].
- Growing adoption of immunotherapy and antibody-drug conjugates.
- High treatment costs, influencing premium pricing strategies.
Price Analysis
Current Pricing
- List price (Wholesale Acquisition Cost, WAC): approximately $7,000 to $8,000 per vial.
- Treatment involves 2.5 mg/kg doses administered every three weeks.
- Estimated average per patient per cycle: $18,000 to $20,000, considering average patient weight.
Pricing Strategy
- GSK maintains premium pricing consistent with biologic treatments.
- Discounts, rebates, and insurance negotiations will affect net prices.
- Biosimilar entry remains unlikely in the near term.
Cost Components
- Manufacturing costs are high due to complex conjugation processes.
- Notable expenses include drug conjugation, distribution, and administration.
- Reimbursement policies influence net revenue and pricing flexibility.
Price Projections (2023–2028)
| Year |
Projected Average Price per Vial |
Estimated Annual Revenue Share |
Assumptions |
| 2023 |
$7,800 |
$600 million |
Launch period, initial market uptake |
| 2024 |
$7,800 |
$800 million |
Expanded approval, growing adoption |
| 2025 |
$7,600 |
$1.1 billion |
Market stabilization, increased treatment cycles |
| 2026 |
$7,500 |
$1.2 billion |
Standardized pricing, competitor dynamics |
| 2027 |
$7,400 |
$1.3 billion |
Continued growth, expanded indications |
| 2028 |
$7,300 |
$1.4 billion |
Potential market saturation in existing indications |
Note: Decreasing prices over time reflect standard biologic price erosion and increased market competition.
Factors Influencing Price and Market Dynamics
- Regulatory developments: New indications or expanded approval may increase demand.
- Market penetration: Uptake rates depend on physician preference and reimbursement policies.
- Competition: Entry of biosimilars or alternative therapies may pressure prices.
- Reimbursement policies: Insurance coverage, including Medicaid and Medicare, influences access and net revenue.
Risks and Opportunities
Risks
- Slower adoption due to safety concerns like keratopathy.
- Patent litigation delaying biosimilar entry.
- Competitive emerging therapies reducing market share.
Opportunities
- Broader indication approval expanding patient population.
- Combination regimen approvals increasing utilization.
- Cost reductions through manufacturing efficiencies.
Key Takeaways
- NDC 16714-0526 (Blenrep) operates in a high-value niche within the multiple myeloma market.
- Current list prices are approximately $7,800 per vial, with healthcare providers and payers experiencing high treatment costs.
- Market projections estimate sales growth reaching $1.4 billion by 2028, contingent on regulatory and competitive factors.
- Pricing will likely soften gradually due to market maturation and patent protections against biosimilar competition.
FAQs
1. What factors could accelerate market uptake of Blenrep?
Expanded indications, positive clinical trial results, and favorable reimbursement terms.
2. How does Blenrep compare to CAR T-cell therapies in pricing?
CAR T therapies often exceed $400,000 per treatment course, making Blenrep relatively more affordable but less potent in some cases.
3. When could biosimilars enter the market?
Potential entry around 2030, depending on patent litigation and biosimilar development timelines.
4. What are the main cost components impacting net revenue?
Research and development, manufacturing complexity, distribution, and payer rebates.
5. How do safety concerns affect pricing?
Adverse effects like keratopathy may impact patient and physician acceptance, influencing market share and pricing flexibility.
References
[1] American Cancer Society. (2022). Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-and-statistics.html
